OXALITEX

The first TEX Core oncology compound to be developed is OxaliTEX, a conjugation of an oxaliplatin Pt(IV) prodrug and texaphyrin, which localizes to solid tumors including ovarian, lung and colorectal cancers.

The lead indication for OxaliTEX is ovarian cancer, the number one cause of gynecological cancer deaths globally.

A NEW ERA FOR CANCER THERAPY

OncoTEX Inc. is progressing the TEX Core platform development, in collaboration with The University of Texas at Austin to develop and commercialize a pipeline of oncology compounds with optimal efficacy for treating a range of different cancers^[1].

TEX Core-developed compounds are designed to be tumor localizing, well-tolerated, MRI-detectable and efficacious in multiple solid tumors, including cancer cells that fail to respond to current therapies^[1].

OXALITEX TARGETS TUMOR CELLS

The novel compound enters and is retained by tumor cells, overcoming multiple mechanisms of resistance, and minimizing toxic side effects^[1,14].

OxaliTEX is a conjugation of texaphyrin and an oxaliplatin Pt(IV) prodrug

OxaliTEX enters the body in an inactive form, known as OxaliTEX Pt(IV)

OxaliTEX is attracted specifically to tumor cells, avoiding healthy cells

It enters the tumor cell – where it is needed

Within the tumor cell, it activates the highly potent oxaliplatin

Oxaliplatin destroys tumor cells including those that are platinum sensitive and platinum resistant

OVERCOMING PLATINUM RESISTANCE

Pre-clinical research has shown OxaliTEX is more effective than traditional platinum-based chemotherapy, with the ability to overcome multifactorial resistance, including reactivation of the mutated p53 tumor suppressor gene, a primary reason current therapies fail^[1].

OxaliTEX is also visible on MRI, meaning physicians can identify tumor locations and monitor response to treatment.

Almost half of all chemotherapy patients are treated with platinum-based drugs such as cisplatin, carboplatin and oxaliplatin^[2].

86% of patients experience side effects from traditional chemotherapy treatments and 27% of those side effects are potentially life threatening^[3].

Drug treatment resistance is responsible for up to 90% of cancer related deaths^[4].

OVARIAN CANCER

An urgent unmet need

The lead indication for OxaliTEX is ovarian cancer, the number one cause of gynaecological cancer deaths globally.

Ultimately, 80-90% of women diagnosed with advanced stage ovarian cancer will develop platinum resistance. OxaliTEX has the ability to kill cancer cells even in platinum resistant tumors^[11].

OncoTEX Inc. plans to utilize a regulatory approval pathway which expedites treatments with orphan drug status.

OxaliTEX addresses an unmet clinical need in platinum-resistant ovarian cancer.

Resistance is a key issue in ovarian cancer with 80-90% of patients becoming resistant, which leads to disease progression^[12].

Across 7 major markets, the ovarian cancer drug market was worth $1.8bn in 2018 and is expected to increase to $6.7bn by 2028^[13].